New blood pump system approved

(HealthDay)—The Impella 2.5 System has been approved by the U.S. Food and Drug Administration to maintain stable heart function and blood circulation during high-risk cardiac operations, the agency said in a news release.

The miniature blood pump is sanctioned for patients during higher-risk procedures such as angioplasty, when a blocked artery is unclogged using an inflated balloon, the agency said.

The system is guided into the of the heart via a catheter that's typically inserted into a leg vein. An external controller and monitor turns the pump on and off, measures heart function and allows doctors to adjust the pump as needed, the FDA said.

People with coronary artery disease commonly have diminished blood flow to the heart, which could lead to serious complications during surgery, the agency said.

The Impella System is produced by Abiomed Inc., based in Danvers, Mass.

Explore further

Heart bypass surgery outperforms new generation stents

More information: The FDA has more about this approval.

Copyright © 2015 HealthDay. All rights reserved.

Citation: New blood pump system approved (2015, March 24) retrieved 2 March 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments